Dr. Katie Murray previews the most anticipated updates in non muscle invasive bladder cancer ahead of the American Urological Association Annual Meeting 2026. She highlights phase 3 trials including POTOMAC and pembrolizumab plus BCG, emphasizing the growing role of combination immunotherapy and the importance of safety in early stage disease. The discussion also covers emerging […]
Dr. Katie Murray highlights key muscle invasive bladder cancer updates ahead of the American Urological Association Annual Meeting 2026, with a focus on postoperative recovery after radical cystectomy. Dr. Murray discusses trials like GI-COFFEE, exploring simple interventions to reduce ileus, and TIDE, which evaluates home IV fluid strategies to decrease dehydration and readmissions. While systemic […]
The management of high-risk, bacillus Calmette-Guérin (BCG)–unresponsive non–muscle invasive bladder cancer (NMIBC) continues to evolve with the integration of novel intravesical therapies, including gene-based approaches. The U.S. Food and Drug Administration (FDA) has approved a label update for nadofaragene firadenovec-vncg (Adstiladrin), introducing an accelerated thawing protocol, allowing thawing in approximately 25 minutes at 25 °C. […]
Dr. Katie Murray and Dr. Erik Goluboff explore the emerging role of FGFR3-targeted therapy in intermediate-risk non–muscle invasive bladder cancer, highlighting the high prevalence of FGFR3 mutations in this population and the potential for more precise, less invasive treatment. Early data with selective FGFR3 inhibition suggest promising response rates with a more favorable safety profile […]
Dr. Katie Murray discusses emerging strategies for non–muscle invasive bladder cancer, particularly in the BCG-naive and high-risk settings. Ongoing trials are exploring combinations of BCG with immunotherapy, alternatives like gemcitabine and docetaxel, and new FDA-approved agents to expand frontline options. Biomarkers, including computational histology (CHAI), may help predict patient response to specific therapies and guide […]
ZUSDURI (mitomycin) delivers durable tumor control in recurrent low‑grade, intermediate‑risk NMIBC, with 79.6% complete responses at three months and 72.2% event-free survival at 24 months. Effective across all EORTC risk groups, it offers a promising option for bladder preservation and long-term disease management.
Dr. Katie Murray and oncology nurse practitioner Laura Bauer discuss the practical challenges of delivering new FDA-approved therapies for non–muscle invasive bladder cancer and why strong collaboration between urology and medical oncology is essential. They highlight strategies to prevent patients from being lost to follow-up, coordinate cystoscopy surveillance, manage expensive drug preparation, and ensure smooth […]
Dr. Katie Murray and GU oncology nurse practitioner Laura Bauer discuss how multidisciplinary collaboration is becoming increasingly important in managing non–muscle invasive bladder cancer. They highlight how integrating medical oncology teams helps manage intravesical therapies, coordinate treatment logistics, and expand access to newer agents such as gemcitabine/docetaxel, nadofaragene firadenovec, N-803, and mitomycin hydrogel. As treatment […]